Dr. Matthew I. Milowsky, MD
Medical Oncology (Medical Oncology Physician)
- Medicare participating
At a glance
- Medical school
- State University of New York Downstate Medical Center (1996)
- Years since graduation
- 30
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 139
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1996Medical school: State University of New York Downstate Medical Center
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Medical Oncology Physician primary
NY license 213906
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Unc Hospitals Chapel Hill, NC
- Unc Health Nash Rocky Mount, NC
Medical groups
- University of North Carolina at Chapel Hill (2,052 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 139
- Services billed
- 612
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 295 | 102 |
| New patient office or other outpatient visit, 45-59 minutes | 36 | 36 |
| New patient office or other outpatient visit, 60-74 minutes | 33 | 33 |
| Established patient office or other outpatient visit, 40-54 minutes | 20 | 17 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Orgovyx (relugolix) | 68 |
| Prednisone Other prescribers in New York, NY | 68 |
| Xtandi (enzalutamide) | 59 |
| Abiraterone Acetate | 46 |
| Nubeqa (darolutamide) | 39 |
| Inlyta (axitinib) | 21 |
| Amlodipine Besylate Other prescribers in New York, NY | 18 |
| Welireg (belzutifan) | 14 |
| Tamsulosin Hcl Other prescribers in New York, NY | 13 |
| Cabometyx (cabozantinib s-malate) | 12 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Industry-funded research
Named as a principal investigator on 5 industry-funded studies in 2025, from 4 companies. The companies reported $122,216 in research payments for these studies, mostly to the institutions running them.
- A phase 2 multicohort openlabel multicenter clinical study evaluating the efficacy and safety of disitamab vedotin RC48ADC alone or in combination with pembrolizumab in subjects with locallyadvanced unresectable or me…
Seagen Inc. - FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3
Eli Lilly and Company · Recruiting · NCT05614739 - A study of enfortumab vedotin ASG22CE as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer
Pfizer Inc. - A phase 2 multi cohort open label multicenter clinical study evaluating the efficacy and safety of disitamab vedotin RC48 adc in subjects with HER2 expressing locally advanced unresectable or metastatic urothelial car…
Seagen Inc. - A phase III randomized, double-blind, multi-center study of adjuvant nivolumab versus placebo in subjects with high risk invasive urothelial carcinoma
E.r. Squibb & Sons, L.l.c.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.